Singapore markets closed

Novo Nordisk A/S (0TDD.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
141.72+0.14 (+0.10%)
At close: 07:14PM BST
Full screen
Previous close141.58
Open141.96
Bid0.00 x 0
Ask0.00 x 0
Day's range141.11 - 142.15
52-week range68.37 - 142.93
Volume43,108
Avg. volume22,405
Market cap322.314B
Beta (5Y monthly)0.17
PE ratio (TTM)0.47
EPS (TTM)3.03
Earnings date07 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Novo Nordisk (NVO) Gains As Market Dips: What You Should Know

    In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.

  • Barrons.com

    Obesity-Drug Developers Look at What’s Next for a $100 Billion Market

    Oppenheimer analyst Jay Olson spent several days last week listening as companies such as Eli Lilly discussed how to improve on blockbusters like Zepbound and Novo Nordisk’s Wegovy.

  • Associated Press Finance

    WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

    The World Health Organization and drugmaker Eli Lilly and Co. are warning people to be wary of fake versions of popular weight-loss and diabetes medicines. WHO said Thursday that it has fielded several reports of fake semaglutide — the active ingredient in Novo Nordisk’s Wegovy and Ozempic — in all geographic regions of the world since 2022. Lilly said in an open letter that it was “deeply concerned” about growing online sales and social media posts involving phony or compounded versions of tirzepatide, the active ingredient behind its drugs Mounjaro and Zepbound.